title: Electrocardiographic changes with ziprasidone.
authors.affiliation: Pfizer, Inc., New York.
authors.forename: Antony
authors.initials: A
authors.lastname: Loebel
authors.affiliation: Pfizer, Inc., New York.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Miceli
authors.affiliation: Pfizer, Inc., New York.
authors.forename: Phillip
authors.initials: P
authors.lastname: Chappell
authors.affiliation: Data Power (DP), Inc., Ringoes, NJ.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Siu
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003627:Data Interpretation, Statistical; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy*; D012107:Research Design / Q000592:standards / Q000706:statistics & numerical data; D015983:Selection Bias; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D005879:Tourette Syndrome / Q000150:complications
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone